Physician profile
Jeff D Atkinson
NPI 1295231850
$7,707.80
in general payments reported to CMS, 2019-2025
32 companies · $3,416 in 2025
The $3,416 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.71 · 2022: $750 · 2023: $1,793 · 2024: $1,732 · 2025: $3,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,988 · Travel and Lodging: $2,854 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,987.65 |
| Travel and Lodging | $2,853.68 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,997.55 | 2023-2025 | Venaseal, Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $1,041.89 | 2022-2025 | Intracept, General - Therapies, Wavewriter Alpha Prime 16 |
| Relievant Medsystems, INC. | $807.80 | 2023 | Intracept |
| Abbvie INC. | $564.09 | 2022-2025 | |
| Baxter Healthcare | $415.83 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.53 | 2023-2025 | Relistor, Trulance, Xifaxan |
| Collegium Pharmaceutical, INC. | $278.33 | 2024-2025 | Belbuca, Xtampza |
| Braeburn INC. | $208.34 | 2023-2024 | Brixadi |
| Nevro Corp. | $119.83 | 2024 | Senza |
| Indivior INC. | $104.47 | 2022-2025 | Sublocade |
| Novo Nordisk INC | $97.42 | 2022-2023 | Rybelsus, Wegovy |
| Exeltis, USA INC. | $96.75 | 2024-2025 | Slynd, Twirla |
| Lilly USA, LLC | $72.81 | 2022-2023 | Mounjaro |
| Supernus Pharmaceuticals, INC. | $70.81 | 2023-2024 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $67.73 | 2022-2025 | Breztri, Farxiga |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $62.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $43.86 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $43.70 | 2023 | Spravato |
| Amgen INC. | $34.01 | 2022-2023 | Repatha, Otezla |
| Saluda Medical Americas, INC. | $30.81 | 2024 | Evoke |
| Kowa Pharmaceuticals America, INC. | $29.20 | 2022-2023 | Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $28.42 | 2023 | |
| Pfizer INC. | $28.41 | 2022-2023 | |
| Edwards Lifesciences Corporation | $27.27 | 2022 | |
| Avanos Medical | $26.72 | 2025 | Generator |
| Spr Therapeutics, INC | $26.07 | 2025 | Sprint Pns System |
| Cranial Technologies, INC | $18.94 | 2023 | Doc Band |
| Horizon Therapeutics Plc | $17.71 | 2021 | |
| Dynavax Technologies Corporation | $17.55 | 2023 | Heplisav-B |
| Glaxosmithkline, LLC. | $17.50 | 2023 | Shingrix, Trelegy Ellipta |
| Stryker Corporation | $13.73 | 2024 | Optablate |
| Painteq LLC | $13.65 | 2024 | Painteq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.